Clinical trials: Atherosclerotic Cardiovascular Diseases
Atherosclerosis, Ischemia Limb
Efficacy and Safety Comparison of the Endovascular and the Hybrid Methods for the Treatment of Prolonged Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D
A recent study, where the authors studied the effectiveness of stenting of prolonged lesions (>200 mm) of the femoral-popliteal segment with nitinol stents (TASC II, D), showed unsatisfactory primary patency rates (45%) within 2…
- Conditions
- Atherosclerosis, Ischemia Limb, Superficial Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- NCT04590131
- Testing
- recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal., recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Vertebral Artery Stenosis
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
This is a prospective, multi-center, registry study exploring the duration of dual antiplatelet therapy (DAPT) after drug-eluting stent(DES) treatment of symptomatic vertebral artery atherosclerotic stenosis.
- Trial name
- M Short DAPT (NCT06683300)
- Testing
- DAPT for 3 months after vertebral artery stenting
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Beijing Tiantan Hospital
Cardiovascular Risk Assessment, Rheumatoid Arthritis (RA)
Twenty-four Hour Movement Behaviors and Atherosclerotic Risk
This observational study aims to investigate how 24-hour movement behaviors are associated with atherosclerotic risk in adults with rheumatoid arthritis. These behaviors include physical activity, sedentary behavior, and sleep.
- Conditions
- Cardiovascular Risk Assessment, Rheumatoid Arthritis (RA), 24-Hour Movement Guidelines
- Trial name
- PASSARO (NCT07774507)
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- São Paulo State University
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Peripheral Vascular Diseases, Arterial Occlusive Diseases
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat…
- Conditions
- Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular
- Trial name
- NCT00041925
- Testing
- CGT003 (E2F Duplex Decoy)
- Where
- 123 sites in United States, Canada
- Volunteers
- 1,400 people
- Sponsor
- Anesiva, Inc.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
- Trial name
- NCT03067441
- Testing
- bempedoic acid
- Where
- 3 sites in United States
- Volunteers
- 1,462 people
- Sponsor
- Esperion Therapeutics, Inc.
Carotid Stenosis
Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control
Cerebrovascular accident (CVA) constitutes a major health public problem. This represents the second cardiovascular death cause. CVA is ischemic in 80% of cases.
- Trial name
- ACABII (NCT02748941)
- Testing
- HITS quantification, Ultrasound examinations, High Resolution MRI
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Hospices Civils de Lyon
Atheroscleroses, Coronary
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease
High-dose statins can reduce mortality and cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD).
- Trial name
- NCT04826354
- Testing
- Rosuvastatin and Ezetimibe, Rosuvastatin
- Where
- 2 sites in South Korea
- Volunteers
- 582 people
- Sponsor
- Korea University Anam Hospital
Coronary Disease, Coronary Arteriosclerosis
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary…
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
- Trial name
- ILLUSTRATE (NCT00134173)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 146 sites in United States, Belgium and 4 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Acute Aortic Syndrome, Aortic Dissection
18F Sodium Fluoride PET/CT in Acute Aortic Syndrome
The purpose of this study is to determine whether Sodium Fluoride imaging (using Positron Emission Tomography-Computed Tomography - PET-CT) is able to predict disease progression in acute aortic syndrome.
- Conditions
- Acute Aortic Syndrome, Aortic Dissection, Penetrating Aortic Ulcer, Intramural Hematoma
- Trial name
- FAASt (NCT03647566)
- Testing
- 18F Sodium Fluoride Positron Emission Tomography / Computed Tomography, CT Aortic Angiogram, Aortic MRI
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Cardiovascular Diseases, Acute MI
Impact of the Genetic Background as a Risk Factor for Atherosclerotic Cardiovascular Disease in the Brazilian Population
The main objective of this project is to evaluate the genomic information previously associated with cardiovascular diseases (CVD) and its importance as an independent risk predictor (expressed in Odds Ratio) when adjusted for…
- Conditions
- Cardiovascular Diseases, Acute MI, Stroke, Peripheral Arterial Disease
- Trial name
- CV-GENES (NCT05515653)
- Testing
- Exposure to genetics (polygenic)
- Where
- 41 sites in Brazil
- Volunteers
- 3,974 people, healthy volunteers welcome
- Sponsor
- Hospital Alemão Oswaldo Cruz
Hypertension, Coronary Atherosclerosis
Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)
In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine…
- Trial name
- NCT00294567
- Testing
- Calcium channel blockers (amlodipine, azelnidipine)
- Where
- Japan
- Volunteers
- 199 people
- Sponsor
- Juntendo University
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Intracranial Arterial Diseases, Stent Restenosis
The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease
The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IS- DES in patients with symptomatic intracranial atherosclerotic stenosis.
- Conditions
- Intracranial Arterial Diseases, Stent Restenosis, Percutaneous Transluminal Angioplasty
- Trial name
- NCT05217459
- Testing
- Self-expanding intracranial drug stent system
- Where
- 14 sites in China
- Volunteers
- 128 people
- Sponsor
- Sinomed Neurovita Technology Inc.
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcer
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
This study aims to gather real-world clinical data demonstrating the continued safety and performance of the a marketed stent graft (Zenith® Alpha Thoracic Endovascular Graft [ZTA]) and collect longer term follow-up to better…
- Trial name
- NCT06094127
- Testing
- Endovascular aortic treatment
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Cook Research Incorporated
Iliac Artery Stenosis
EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
- Trial name
- ORION (NCT00896337)
- Testing
- Epic™ Nitinol Stent System, Anti-platelet therapy, Anti-coagulation therapy
- Where
- 28 sites in United States
- Volunteers
- 125 people
- Sponsor
- Boston Scientific Corporation
Cerebrovascular Disease
Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis
The study aims to determine whether tissue kallikrein (TK) is efficacy for preventing the long-term in-stent restenosis (ISR) after stenting of symptomatic atherosclerotic stenosis of the middle cerebral artery (MCA) M1 segment
- Trial name
- NCT01558245
- Testing
- tissue kallikrein
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Jinling Hospital, China
Stroke, Intracranial Atherosclerotic Stenosis
Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study
The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6…
- Trial name
- EAST-sICAS (NCT06052020)
- Testing
- Alirocumab, Atorvastatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Atherosclerotic Cardiovascular Disease
Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques
Lipid accumulation, with mostly emphasized role of low-density lipoprotein cholesterol (LDL-C), is the pathogenetic cornerstone of atherosclerotic cardiovascular disease.
- Trial name
- NCT05639218
- Testing
- Inclisiran
- Where
- Latvia
- Volunteers
- 50 people
- Sponsor
- Pauls Stradins Clinical University Hospital